J&J: towards acquisition of Proteologix for $850 million
May 17, 2024 at 06:34 pm IST
Share
Johnson & Johnson has announced the acquisition of Proteologix, a privately-held biotech company specializing in bispecific antibodies for immune diseases, for $850 million, with a potential additional milestone payment.
Proteologix has two bispecific antibodies in development: PX128, targeting IL-13 and TSLP, for moderate-to-severe atopic dermatitis (AD) and asthma, ready for Phase 1, and PX130, targeting IL-13 and IL-22, in preclinical development for moderate-to-severe AD.
The acquisition also includes other bispecific antibody programs for various diseases, strengthening J&J's capabilities in immune therapies.
'Integrating Proteologix's bispecific antibodies into our pipeline is an important first step in delivering on our commitment to people living with AD', said Candice Long, Global Vice President, Immunology, Johnson & Johnson.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).